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Plopidogrel Effect on Platelet
Eactivity in Patients With Stent Thrombosis
esults of the CREST Study
aul A. Gurbel, MD, FACC, Kevin P. Bliden, BS, Waiel Samara, MD Jason A. Yoho, MD,
evin Hayes, MD, Mulugeta Z. Fissha, MD, Udaya S. Tantry, PHD
altimore, Maryland
OBJECTIVES We investigated whether patients who suffered subacute stent thrombosis (SAT) have higher
post-treatment reactivity than those who do not encounter stent thrombosis.
BACKGROUND High post-treatment platelet reactivity has been reported after coronary stenting after
clopidogrel therapy and may be an important factor in the occurrence of SAT.
METHODS We identified patients with SAT treated at two tertiary care centers over a 1.5-year period.
Light transmittance aggregation induced by adenosine diphosphate (ADP) and arachidonic acid,
total and activated glycoprotein (GP) IIb/IIIa after stimulation with ADP, and vasodilator-
stimulated phosphoprotein phosphorylation levels to measure P2Y12 receptor inhibition were
determined (n  20) and compared with an age-matched group of patients without SAT (n
 100). High post-treatment platelet reactivity was defined as 75th percentile ADP-
induced aggregation in the group without SAT.
RESULTS The SAT patients had higher mean platelet reactivity than those without SAT by all
measurements (p  0.05): 49  4% versus 33  2% for 5 mol/l ADP-induced aggregation
and 65  3% versus 51  2% for 20 mol/l ADP-induced aggregation (p  0.001), 69 
5% versus 46  9% for P2Y12 reactivity ratio (p  0.03), and 138  19 mean fluorescence
intensity (MFI) versus 42  4 MFI for stimulated GP IIb/IIIa expression (p  0.001). Of
patients with SAT, 60% had high platelet reactivity.
CONCLUSIONS High post-treatment platelet reactivity and incomplete P2Y12 receptor inhibition are risk
factors for SAT. Measures to uniformly determine platelet reactivity after coronary stenting
and treatment strategies to improve P2Y12 receptor inhibition in patients with high
post-treatment platelet reactivity should be further investigated. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.05646:1827–32) © 2005 by the American College of Cardiology Foundation
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tlopidogrel and aspirin are the major antiplatelet drugs of
hoice to prevent stent thrombosis (SAT) (1). Reports
ndicate that acute and subacute thrombosis are significant
linical problems despite therapy with thienopyridines and
spirin (2–4). We have recently demonstrated that a signif-
cant percentage of patients after stent implantation had
igh post-treatment platelet reactivity (5). Furthermore, we
lso demonstrated that pretreatment platelet reactivity
trongly affected the final platelet reactivity after clopidogrel
herapy (5,6). Recent studies have suggested that non-
esponsiveness to clopidogrel and high platelet reactivity
ight be risk factors for post-stent ischemic events and
tent thrombosis (7–9). These findings suggest that an
nsufficient anti-platelet effect might occur in a percentage
f patients undergoing stenting treated with clopidogrel,
nd those patients with high reactivity despite clopidogrel
herapy are at the greatest risk of ischemic events.
We hypothesized that patients who have suffered stent
hrombosis have higher post-treatment platelet reactivity
han those who do not encounter stent thrombosis. To
nvestigate this hypothesis, we measured platelet reactivity
From the Sinai Center for Thrombosis Research, Baltimore, Maryland. This study
as supported by a grant from Astra Zeneca LP, Wilmington, Delaware.e
Manuscript received December 22, 2004; revised manuscript received July 11,
005, accepted July 19, 2005.y multiple methods in patients receiving clopidogrel ther-
py who had experienced stent thrombosis and compared
his group with a group of age-matched patients who had
ndergone stent implantation without the occurrence of
hrombosis.
ETHODS
atients and blood samples. This study was approved by
he investigational review boards of our respective hos-
itals. We identified all of the cases of stent thrombosis
n  30) by searching the medical records of patients who
nderwent coronary stenting in the last 1.5 years at the
inai Hospital of Baltimore and Union Memorial Hos-
ital, Baltimore, Maryland. Among the 30 SAT patients,
0 patients underwent analyses of platelet reactivity.
tent thrombosis was defined by the sudden onset of
oronary artery occlusion in a stented vessel resulting in
ospitalization and judged by the treating intervention-
list as due to thrombosis.
We compared the platelet reactivity in patients with
AT (n  20) to patients without SAT (n  100). In
atients without SAT, platelet studies were performed 5
o 14 days after procedure and these patients were
nrolled consecutively. In patients with SAT, the average
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nitial blood drawn for laboratory evaluation was 218 
04 days. In-hospital patients identified with SAT had
lood drawn at day five after the procedure. In patients
ith SAT already receiving a maintenance dose of
lopidogrel (75 mg q.d.), blood samples were evaluated
n the day of arrival at our center. Those patients (n  2)
ot receiving clopidogrel at the time of the study were
eloaded with 300 mg, maintained on 75 mg/day, and
eturned for blood sampling five days later.
Blood was drawn with a 21-gauge needle and placed
nto Vacutainer blood collecting tubes (Becton Dickin-
on, Franklin Lakes, New Jersey) containing 3.8% triso-
ium citrate after discarding the first 2 to 3 ml of
ree-flowing blood. The Vacutainer tube was filled to
apacity and gently inverted three to five times to ensure
omplete mixing of the anticoagulant. No patients in the
tudy had been receiving glycoprotein (GP) IIb/IIIa
nhibitors or anticoagulants within 96 h of blood sam-
ling. All patients were receiving aspirin (81 to 325 mg
.d.) except two patients in the SAT group.
latelet reactivity measurements. PLATELET AGGREGA-
ION. Platelet aggregation was determined by conventional
ight transmittance aggregometry (model 490, Chronolog
ggregometer with AggregoLink software; Havertown,
ennsylvania) in response to 5 and 20 mol/l ADP and 1
mol/l arachidonic acid with standard methods as previ-
usly described (10).
P IIb/IIIa RECEPTORS. The surface expression of platelet
eceptors was determined by whole blood flow cytometry
ith a multicolor analysis method (Immunocytometry
ystems, Cytometry Source Book, BD Biosciences, San
iego, California) with the following monoclonal anti-
odies: fluorescein isothiocyanate (FITC)-conjugated
AC-1 (recognizes the active GP IIb/IIIa receptor) and
-phycoerythrin (R-PE) conjugated CD41a (recognizes
he total GP IIb/IIIa receptor population). Antibodies
ere obtained from BD Biosciences. The blood-citrate
ixture was stimulated with 5 mol/l ADP for 2 min.
aturating concentrations of respective antibodies were
dded to unstimulated and simulated blood, and the
ubes were incubated at room temperature for 20 min in
he dark. The labeled samples were fixed by the addition
f 1% buffered paraformaldehyde and stored at 4°C for at
east 2 h. The labeled samples were analyzed by a Becton
Abbreviations and Acronyms
ADP  adenosine diphosphate
GP  glycoprotein
MFI  mean fluorescence intensity
PGE1  prostaglandin E1
SAT  stent thrombosis
VASP  vasodilator-stimulated phosphoproteinickinson FACScan flow cytometer, set up to measure uuorescence light scatter that was calibrated daily with
uorescence beads for the multicolor flow cytometer
etup (CaliBRITE 3, BD Biosciences). After setting the
ate around platelets, FL1(FITC)/FL2(R-PE) compen-
ations were adjusted. All the variables were collected
ith four-decade logarithmic amplification. The data
ere collected in list mode and then analyzed with CELL
uest Software (Becton Dickinson Biosciences). Total
nd activated GP IIb/IIIa receptor levels were expressed
s log mean fluorescence intensity (MFI) (11). Measure-
ent of the PAC-1 binding to the activated GP IIb/IIIa
eceptor on platelets is an established method to deter-
ine the effect of ADP on the P2Y12 receptor. Activated
P IIb/IIIa receptor binding to fibrinogen is the final
tep during platelet aggregation in response to ADP.
herefore, the measurement of activated GP IIb/IIIa
eceptor expression directly indicates the effectiveness of
DP binding to P2Y12 receptors (12).
2Y12 reactivity ratio. The measurement of vasodilator-
timulated phosphoprotein (VASP) phosphorylation levels
s a marker of P2Y12 receptor reactivity and, thus,
lopidogrel-induced inhibition (9,13–16). Prostaglandin E1
PGE1) increases VASP phosphorylation levels by stimula-
ion of adenylate cyclase. Binding of ADP to P2Y12 leads to
i-coupled inhibition of adenylate cyclase. Therefore, the
ddition of ADP to PGE1-stimulated platelets reduces
GE1-induced VASP phosphorylation levels. If P2Y12
eceptors were successfully inhibited by clopidogrel, addi-
ion of ADP will not reduce the PGE1-stimulated VASP
hosphorylation levels. This principle is used in the present
ethod where phosphorylated VASP levels were quantified
ith labeled monoclonal antibodies by flow cytometry with
he Platelet VASP-FCM kit (Biocytex Inc., Marseille,
rance). The P2Y12 reactivity ratio is calculated after
easuring the VASP phosphorylation levels after stimula-
ion with PGE1 (MFI PGE1) and also PGE1ADP (MFI
GE1  ADP). The P2Y12 reactivity ratio  ([MFI
GE1]  [MFI PGE1  ADP]/[MFI PGE1])  100%.
hus, as the ratio falls, there is clopidogrel-induced inhibi-
ion of the P2Y12 receptor.
efinitions. High post-treatment platelet reactivity was
efined as 75th percentile for 5 and 20 mol/l ADP-
nduced aggregation as measured in the group without
AT. This definition is stricter than our previous definition,
here the highest tertile of aggregation was used to define
igh platelet reactivity (5). High post-treatment platelet
eactivity was also defined as75th percentile of VASP and
timulated active GP IIb/IIIa expression values. Aspirin
esistance was defined as 20% change in light transmit-
ance after stimulation with arachidonic acid (16).
tatistical analysis. Comparisons were made between
roups by unpaired t tests for continuous variables and by
isher exact test for categorical variables (statistical software
y StatSoft Inc., Tulsa, Oklahoma). Regression analysis
ith calculation of the Pearson correlation coefficient was
sed to correlate platelet aggregation with the other markers
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November 15, 2005:1827–32 Clopidogrel, Platelet Reactivity, and Stent Thrombosiseasured (statistical software by StatSoft Inc.). The Wilks-
hapiro test was used to assess conformity with a normal
istribution. On the basis of the normal distribution of data,
he mean  SD and mean  SE were used, and p  0.05
as considered significant.
ESULTS
atients. A total of 5,355 interventional coronary proce-
ures were performed at the two hospitals over an 18-
onth period, and 30 patients (0.6%) were identified as
aving SAT. Among these patients, there were 3 deaths, 5
atients could not be contacted, 2 could not participate
ecause of clopidogrel allergy (skin rash), and the remaining
0 patients agreed to participate in the study. Among these
0 patients, 18 were receiving a 75-mg maintenance dose of
lopidogrel and 2 patients were re-treated with clopidogrel.
f 20 SAT patients, 18 were on aspirin therapy (81 to 325
g/day). The mean time to SAT (time from the day of
rocedure to the development of SAT) was 23  16 days.
emographics. The patient demographics and procedural
haracteristics of both groups are shown in Tables 1 and 2,
espectively. Among the interventions performed in patients
ithout SAT, 2 patients were admitted with myocardial
nfarction and 11 patients had unstable angina. The remain-
er of the patients had stable angina, and the procedures
ere performed electively. Twelve of the procedures result-
ng in SAT were performed emergently (myocardial infarc-
ion in seven patients and unstable angina in five patients).
he remainder had stable angina. The ages of both groups
able 1. Patient Demographics
SAT
(n  20)
No SAT
(n  100) p Value
ge (yrs) 65  11 62  12 NS
ace (caucasian), n (%) 10 (50) 78 (78) 0.04
ender (male), n (%) 10 (50) 66 (66) NS
isk factors/medical history, n (%)
Smoking 9 (45) 57 (57) NS
Family history of CAD 16 (80) 50 (50) 0.06
Hypertension 15 (75) 79 (79) NS
Hyperlipidemia 15 (75) 80 (80) NS
Diabetes 12 (60) 42 (42) NS
Prior myocardial infarction 12 (60) 42 (42) NS
Prior CABG 5 (25) 26 (26) NS
Prior PTCA 4 (20) 38 (38) NS
aseline medications, n (%)
Beta-blockers 17 (85) 85 (85) NS
ACE inhibitors 15 (75) 66 (66) NS
Calcium blockers 5 (25) 22 (22) NS
ipid-lowering agents
3A4 pathway metabolized 11 (55) 54 (54) NS
Non-3A4 pathway metabolized 5 (25) 29 (29) NS
CE  angiotensin-converting enzyme; CABG  coronary artery bypass graft
urgery; CAD  coronary artery disease; PTCA  percutaneous coronary angio-
lasty; SAT  stent thrombosis.ere the same. Patients with SAT had a non-significantly
reater incidence of family history of coronary artery disease.
ematological data did not differ between groups (data not
hown). The ejection fraction was lower, and the total lesion
ength was greater in the SAT group. Drug-eluting stents
ere more commonly used in patients without SAT.
latelet data. Platelet aggregation in response to 5 and 20
mol/l ADP was higher in the group with SAT as
ompared with the group without SAT (Figs. 1A and 1B, p
0.05 for both 5 and 20 mol/l ADP-induced aggrega-
ion). Patients with SAT had greater active GP IIb/IIIa
xpression and a higher P2Y12 reactivity ratio, whereas total
P IIb/IIIa expression was not significantly different be-
ween groups (Table 3).
The estimated prevalence of high post-treatment platelet
eactivity was 65% and 60%, as measured by 5 and 20
mol/l ADP-induced aggregation in SAT patients, respec-
ively (Figs. 1A and 1B). The r value comparing 5 mol/l
DP-induced aggregation to 20 mol/l ADP-induced
ggregation was 0.93. The P2Y12 reactivity ratio by VASP
ssay correlated with 20 mol/l ADP-induced aggregation
r  0.57, p  0.019). The correlation of stimulated active
P IIb/IIIa expression with 20 mol/l ADP-induced
ggregation was weaker (r  0.29, p  0.23). Fifty percent
f patients with SAT met the definition of high post-
reatment platelet reactivity on the basis of VASP values,
hereas 40% of the patients met the definition with respect
o activated GP IIb/IIIa expression. All patients were
esponsive to aspirin, except one in the SAT group (54%
rachidonic acid-induced aggregation). Aggregation by ar-
chidonic acid was 4  2% in the non-SAT group versus 3
able 2. Procedural Characteristics
SAT
(n  20)
No SAT
(n  100) p Value
jection fraction (%) 40  10 53  5  0.001
umber of vessels
treated
1.3  0.4 1.5  0.5 NS
esion morphology
De novo, n (%) 20 (100) 90 (90) NS
esion location, n (%)
LAD 5 (30) 25 (25) NS
CX 3 (15) 20 (20) NS
RCA 12 (60) 39 (39) 0.04
SVG 0 (0) 16 (16) NS
tent types
Drug-eluting, n (%) 6 (30) 70 (70)  0.001
Bare-metal, n (%) 14 (70) 30 (30)  0.001
Reference vessel
diameter (mm)
2.8  0.3 3.0  0.5 NS
Total lesion length
(mm)
24  6 18  7 0.004
Pre-stenosis (%) 94  7 88  10 NS
Post-stenosis (%) 9  12 4  6 NS
X  circumflex artery; LAD  left anterior descending artery; RCA  right
oronary artery; SAT  stent thrombosis; SVG  saphenous vein graft.2% (p  NS).
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intensity; SAT  stent thrombosis.
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ith established measurements of platelet reactivity, we
emonstrated that post-treatment platelet reactivity is
igher in patients who had suffered SAT as compared with
hose without SAT, despite the presence of clopidogrel
herapy in both groups. We found higher mean platelet
ggregation induced by two concentrations of ADP as well
s higher expression of active GP IIb/IIIa after stimulation
y ADP in SAT patients. The VASP assay is a direct
easure of P2Y12 reactivity and, therefore, directly assesses
he intrinsic functional response of the receptor. Our results
trongly suggest that the P2Y 12 receptor is not adequately
nhibited by clopidogrel in a large percentage of patients
ho had experienced SAT. This assay might be useful in
ose titration studies to tailor clopidogrel therapy in patients
efore discharge. The demonstration of a higher P2Y12
eactivity ratio in patients with SAT strongly suggests lower
eceptor occupancy by clopidogrel, thus implying insuffi-
ient active metabolite generation. All of the data strongly
upport high platelet reactivity as a risk factor for the
evelopment of SAT.
Subacute stent thrombosis is a serious complication with
ncidences ranging from 0.4% to 3% in high-risk patients
2–4). A recent study reported the incidence to be only 0.4%
n 500 patients treated with a sirolimus-eluting stent (3).
he 0.6% incidence of SAT in our study is in agreement
ith these data. Many factors are likely to affect the
evelopment of an acute thrombotic episode in a recently
tented vessel (2). Most of the patients with SAT in our
tudy had their index procedure performed emergently and
ad long lesions. These risk factors are also supported by
ther studies (2,4).
Our results are concordant with Muller et al. (7), who
rospectively examined 105 patients undergoing elective
ercutaneous coronary intervention and found that two
atients subsequently developed stent thrombosis, both of
hich were non-responders to clopidogrel. The latter in-
estigators also reported high platelet aggregation in three
ther patients not enrolled in the study who had experi-
nced SAT. These findings were supported in a prospective
No SAT
(n  100) p Value
33  2 0.001
51  2 0.001
er 0 non-responders
46  9 0.03
15  3 NS
42  4 0.001
513  30 NS
729  60 NSigure 1. (A) 5 mol/l adenosine diphosphate (ADP)-induced platelet
ggregation in patients with stent thrombosis (SAT) and without stent
hrombosis (No SAT). Dashed line indicates 75th percentile in non-SAT
roup. (B) 20 mol/l ADP-induced platelet aggregation in patients withable 3. Measurements of Platelet Reactivity
SAT
(n  20)
TA (5 mol/l ADP) (%) 49  4
TA (20 mol/l ADP) (%) 65  3
TA (1 mmol/l arachidonic acid) 1 non-respond
2Y12 reactivity ratio (%) 69  5
P IIb/IIIa (MFI)
Unstimulated 9  1
Stimulated 138  19
D 41 (MFI)
Unstimulated 515  31
Stimulated 770  38ht transmittance aggregometry; MFI  mean fluorescence
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ndergoing stenting with ST-segment elevation myocardial
nfarction in the lowest quartile of clopidogrel responsive-
ess were at increased risk for cardiovascular events after
ischarge.
We have previously defined clopidogrel resistance as
10% absolute change in aggregation compared with base-
ine (5). The current study, however, was not prospective
ith respect to the SAT group and, therefore, a baseline
easurement of platelet reactivity was not recorded. Given
he overall low event rate of SAT, the number of patients
equired to assess the relation of clopidogrel resistance to
AT in a prospective investigation was prohibitively large.
herefore, the incidence of clopidogrel resistance in SAT
atients cannot be determined in the present study; how-
ver, the higher platelet reactivity measured in SAT patients
ith multiple techniques strongly suggests that platelets
ere inadequately inhibited by clopidogrel in these patients.
Although there is no accepted definition of aspirin
esistance, various measurements of platelet function in
atients receiving aspirin have been correlated to a greater
isk of cardiovascular events. The prevalence of aspirin
esistance has been reported to be between 5% and 45%
17–20). Of interest in our study, platelet reactivity to 1.0
mol/l arachidonic acid was extremely low. Our results are
iscordant with observations by other investigators (17,20).
um et al. (17) estimated aspirin resistance by using a
ombination of responsiveness to both ADP and a slightly
igher dose of arachidonic acid (1.6 mmol/l). In their study,
ean aggregation in response to arachidonic acid was 11.4
10.3%, as compared with approximately 4% in our study.
he lower arachidonic acid concentration in our study may
n part explain why we found only 1 of 118 met the criteria
or resistance as compared with 5.5% in their study. The
ffect of aspirin to block cyclooxygenase activity is likely
uch more uniform, whereas the effect on platelet aggre-
ation as measured by agonists other than arachidonic acid
s influenced by many factors. Therefore, the incidence of
spirin resistance (lack of inhibition of cyclooxygenase) is
robably rare, as reflected in the present study.
Although we believe that high post-stent platelet reac-
ivity is a risk factor for SAT, at this time, significant
rospective data are lacking to recommend routine screen-
ng on all patients undergoing stenting. Larger-scale inves-
igations are needed to support our findings. Finally, high
ost-treatment platelet reactivity might be due to incom-
lete inhibition of the P2Y12 receptor by the current dosing
f clopidogrel. We have demonstrated that a 600-mg
lopidogrel loading dose results in superior early platelet
nhibition as compared with a 300-mg dose (21); however,
here are no data available regarding the effect of a higher
aintenance dose and platelet reactivity. Future therapies
ith new P2Y12 inhibitors promise less variability in post-
reatment reactivity (22).
tudy limitations. Platelet studies were performed at dif-
erent times in non-SAT and SAT patients. Non-SATatients were enrolled and studied prospectively, whereas
atients with SAT were identified retrospectively and sub-
equently studied. The analyses of platelet reactivity con-
ucted at different intervals from the index procedure might
ffect the results. However, we have previously demon-
trated that clopidogrel responsiveness is lowest and platelet
eactivity is highest early after stenting (5). Therefore, this
act would only strengthen our hypothesis, because at a later
ate, we would expect the non-SAT patients to have even
igher clopidogrel responsiveness.
In conclusion, the current study strongly suggests that
igh platelet reactivity and incomplete inhibition of P2Y12
eceptor are risk factors for SAT. Measures to uniformly
etermine platelet reactivity after coronary stenting and
reatment strategies to improve platelet inhibition in pa-
ients with high post-treatment platelet reactivity should be
urther investigated.
eprint requests and correspondence: Dr. Paul A. Gurbel, Sinai
enter for Thrombosis Research, Hoffberger Building, Suite 56,
401 West Belvedere Avenue, Baltimore, Maryland 21215.
-mail: pgurbel@lifebridgehealth.org.
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